These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1412727)

  • 1. The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation.
    Symington FW; Symington BE; Liu PY; Viguet H; Santhanam U; Sehgal PB
    Transplantation; 1992 Sep; 54(3):457-62. PubMed ID: 1412727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease.
    Imamura M; Hashino S; Kobayashi H; Kubayashi S; Hirano S; Minagawa T; Tanaka J; Fujii Y; Kobayashi M; Kasai M
    Bone Marrow Transplant; 1994 Jun; 13(6):745-51. PubMed ID: 7920309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of serum cytokines after allogeneic bone marrow transplantation: interleukin-5 as a potential marker of acute graft-versus-host disease.
    Imoto S; Oomoto Y; Murata K; Das H; Murayama T; Kajimoto K; Sugimoto T; Gomyo H; Nakagawa T; Nishimura R; Koizumi T
    Int J Hematol; 2000 Jul; 72(1):92-7. PubMed ID: 10979216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum cytokine levels after HLA-identical bone marrow transplantation.
    Liem LM; van Houwelingen HC; Goulmy E
    Transplantation; 1998 Oct; 66(7):863-71. PubMed ID: 9798695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
    Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
    Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Nakamura H; Komatsu K; Ayaki M; Kawamoto S; Murakami M; Uoshima N; Yagi T; Hasegawa T; Yasumi M; Karasuno T; Teshima H; Hiraoka A; Masaoka T
    J Allergy Clin Immunol; 2000 Jul; 106(1 Pt 2):S45-50. PubMed ID: 10887333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the severity of graft-versus-host disease from interleukin-10 levels after bone marrow transplantation.
    Takatsuka H; Takemoto Y; Okamoto T; Fujimori Y; Tamura S; Wada H; Okada M; Yamada S; Kanamaru A; Kakishita E
    Bone Marrow Transplant; 1999 Nov; 24(9):1005-7. PubMed ID: 10556960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation.
    Ferrà C; de Sanjosé S; Gallardo D; Berlanga JJ; Rueda F; Marìn D; de la Banda E; Ancìn I; Peris J; Garcìa J; Grañena A
    Haematologica; 1998 Dec; 83(12):1082-7. PubMed ID: 9949625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of T helper 1, T helper 2, and inflammatory cytokine expression in patients after allogeneic bone marrow transplantation: relationship with the occurrence of acute graft-versus-host disease.
    Carayol G; Bourhis JH; Guillard M; Bosq J; Pailler C; Castagna L; Vernant JP; Pico JL; Hayat M; Chouaib S; Caignard A
    Transplantation; 1997 May; 63(9):1307-13. PubMed ID: 9158026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble interleukin 2 receptors in patients after bone marrow transplantation.
    Siegert W; Josimovic-Alasevic O; Schwerdtfeger R; Baurmann H; Schmidt CA; Musch R; Schmid HJ; Hartmann R; Henze G; Huhn D
    Bone Marrow Transplant; 1990 Aug; 6(2):97-101. PubMed ID: 2207458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of interleukin-12 in the development of acute graft-versus-host disease in bone marrow transplant patients.
    Yabe M; Yabe H; Hattori K; Shimizu T; Matsumoto M; Morimoto T; Yasuda Y; Inoue H; Kato S; Nishimura T
    Bone Marrow Transplant; 1999 Jul; 24(1):29-34. PubMed ID: 10435731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase of interleukin-18 serum levels after engraftment correlates with acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation.
    Scholl S; Sayer HG; Mügge LO; Kasper C; Pietraszczyk M; Kliche KO; Clement JH; Höffken K
    J Cancer Res Clin Oncol; 2004 Dec; 130(12):704-10. PubMed ID: 15365821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of interleukin 6, interleukin 8, and C-reactive protein after human allogeneic bone marrow transplantation.
    Schwaighofer H; Herold M; Schwarz T; Nordberg J; Ceska M; Prior C; Nachbaur D; Weyrer W; Brankova J; Eibl B
    Transplantation; 1994 Aug; 58(4):430-6. PubMed ID: 8073511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperacute graft-versus-host disease accompanied by increased serum interleukin-6 levels.
    Imamura M; Hashino S; Kobayashi S; Kobayashi H; Tanaka J; Imai K; Kasai M; Sakurada K; Miyazaki T
    Int J Hematol; 1994 Jul; 60(1):85-9. PubMed ID: 7919241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation.
    Remberger M; Ringdén O
    Transplantation; 1995 Dec; 60(11):1293-9. PubMed ID: 8525524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
    Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
    Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
    Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokines involved in graft-versus-host disease.
    Imamura M; Tanaka J; Hashino S; Kobayashi H; Hirano S; Minagawa T; Imai K; Kobayashi S; Fujii Y; Kasai M
    Hokkaido Igaku Zasshi; 1994 Nov; 69(6):1348-53. PubMed ID: 7705747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
    Zhao J; Zhao XY; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2497-502. PubMed ID: 16321278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.